GlassScriptPhysician profile
Amy Spangler
NPI 1205045952
$8,206.54
in general payments reported to CMS, 2019-2025
26 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,109 · 2022: $1,445 · 2023: $1,686 · 2024: $2,336 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,457 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.69 |
| Education | $195.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,642.39 | 2021-2025 | |
| Janssen Biotech, INC. | $865.75 | 2021-2025 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $684.81 | 2021-2025 | |
| Ucb, INC. | $668.74 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $450.25 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $433.07 | 2022-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $407.17 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $379.71 | 2021-2025 | Ilumya |
| Galderma Laboratories, L.P. | $353.52 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $337.48 | 2021-2025 | |
| Leo Pharma INC. | $303.87 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $282.75 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $276.86 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $272.74 | 2023-2024 | Vtama |
| Lilly USA, LLC | $200.43 | 2021-2025 | Taltz, Ebglyss |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.37 | 2022-2025 | Spevigo, Cyltezo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $120.48 | 2022-2025 | Cabtreo, Siliq, Arazlo |
| Vyne Pharmaceuticals INC. | $95.00 | 2021 | |
| Almirall LLC | $93.83 | 2021-2025 | Klisyri |
| Strata Skin Sciences, INC. | $37.66 | 2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $34.34 | 2024-2025 | Zoryve |
| Hill Dermaceuticals, INC. | $29.98 | 2023 | Tolak |
| Organon LLC | $29.12 | 2025 | Vtama |
| Lnhc, INC | $19.67 | 2025 | Zelsuvmi |
| Fresenius Kabi USA, LLC | $17.71 | 2023 | Idacio |
| Dermira, INC. | $16.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Spangler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.